These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6422006)

  • 1. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
    Logothetis CJ; Samuels ML; von Eschenbach AC; Trindade A; Ogden S; Grant C; Johnson DE
    J Clin Oncol; 1983 Jun; 1(6):368-79. PubMed ID: 6422006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
    Logothetis CJ; von Eschenbach AC; Samuels ML; Trindade A; Johnson DE
    Cancer Treat Rep; 1982 Jan; 66(1):57-63. PubMed ID: 7053267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
    Yoshimoto J; Ochi J; Tanahashi T; Nanba K; Saegusa M; Hara M; Akagi T; Obama T; Tsushima T; Ozaki Y
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):434-9. PubMed ID: 2434029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
    Inoue K; Horikoshi N; Mukaiyama T; Ogawa M; Kuraishi Y
    Gan No Rinsho; 1989 Mar; 35(4):481-5. PubMed ID: 2654442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
    Kasimis BS; Moran EM; Miller JB; Forbes KA; Kaneshiro CA; Poblet MT; Williams JL
    Cancer Treat Rep; 1983 Oct; 67(10):937-9. PubMed ID: 6688755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C.
    Babaian RJ; Hsu SD
    Urology; 1984 Mar; 23(3):272-5. PubMed ID: 6546626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Kasimis BS; Miller JB; Kaneshiro CA; Forbes KA; Moran EM; Metter GE
    J Clin Oncol; 1985 Mar; 3(3):385-92. PubMed ID: 3838343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
    Blumenstein B; Crawford ED; Saiers JH; Stephens RL; Rivkin SE; Coltman CA
    J Urol; 1993 Aug; 150(2 Pt 1):411-3. PubMed ID: 8326565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy in metastatic tumors of unknown origin. 5-Fluorouracil, adriamycin and mitomycin C for adenocarcinomas and adriamycin, vinblastine and mitomycin C for anaplastic carcinomas.
    Sulkes A; Uziely B; Isacson R; Brufman G; Biran S
    Isr J Med Sci; 1988; 24(9-10):604-10. PubMed ID: 3204009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
    van der Gaast A; Verweij J; Planting AS; Stoter G
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):765-8. PubMed ID: 3383976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
    Krook JE; Jett JR; Fleming TR; Dalton RJ; Marschke RF; Cullinan SA; Windschitl HE; Everson LK; Brunk FS; Laurie JA
    J Clin Oncol; 1985 Jun; 3(6):842-8. PubMed ID: 3839263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung.
    Shaw MT; Shaw MK
    Cancer; 1987 Sep; 60(6):1190-3. PubMed ID: 3040207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experiences with polychemotherapy MAF (mitomycin C, adriablastine, 5-fluorouracil) in progressing metastasized prostate cancer].
    Burk K; Gropp C; de Riese W; Löbenau S
    Helv Chir Acta; 1985 Sep; 52(3-4):601-3. PubMed ID: 3934112
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
    Burk K; Gropp C; Rodeck G
    Urologe A; 1983 Sep; 22 Suppl():347-9. PubMed ID: 6415885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined 5-fluorouracil, adriamycin and mitomycin C in the management of adenocarcinoma metastasizing to the liver from an unknown primary site.
    al-Idrissi HY
    J Int Med Res; 1990; 18(5):425-9. PubMed ID: 2124191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
    J Clin Oncol; 1986 Dec; 4(12):1794-8. PubMed ID: 2946815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
    Gibson MK; Holcroft CA; Kvols LK; Haller D
    Oncologist; 2005 Feb; 10(2):132-7. PubMed ID: 15709215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
    Laurie JA; Hahn RG; Therneau TM; Patel SR; Mailliard JA; Windschitl HE; Twito DI; Morton RF; Krook JE
    Cancer; 1992 Mar; 69(6):1440-4. PubMed ID: 1540881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
    Sternberg CN; Magill GB; Sordillo PP; Cheng EW
    Am J Clin Oncol; 1984 Oct; 7(5):529-33. PubMed ID: 6391145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
    Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
    Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.